SCHEMBL1967047

SCHEMBL1967047

CCc1cc2c(N3CCn4cnnc4C3)nc(Cl)nc2s1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.47
HRH4 Q9H3N8 1/20 0.41
HTT P42858 3/20 0.40
MEN1 O00255 10/20 0.39
KMT2A Q03164 7/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
TSHR P16473 2/20 0.38
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
P2RY12 Q9H244 4/20 0.38
TMIGD3 P0DMS9 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1968624 0.83 HTR6 (0.47) HTR6HRH4HTTMEN1KMT2A
SCHEMBL12409612 0.81 HTR6 (0.50) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1967030 0.80 HTR6 (0.44) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1969862 0.79 P2RY12 (0.48) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1967925 0.79 P2RY12 (0.43) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1970024 0.78 P2RY12 (0.62) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1967052 0.78 HTR6 (0.47) HTR6HTTMEN1KMT2ASMN1; SMN2
SCHEMBL1969602 0.76 P2RY12 (0.53) HTR6HRH4HTTMEN1KMT2A
SCHEMBL4719406 0.75 HTR6 (0.55) HTR6HRH4HTTMEN1KMT2A
SCHEMBL1965596 0.74 P2RY12 (0.39) HTR6HRH4HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2011-07-07 US disclosed
EP-2334689-A2 FUSED HETEROCYCLIC COMPOUND LG Life Sciences Ltd. (KR) 2011-06-22 EP disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed
WO-2010027236-A2 FUSED HETEROCYCLIC COMPOUND LG LIFE SCIENCES LTD. (KR) 2010-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166121-A1 FUSED HETEROCYCLIC COMPOUND F2, PF4, F11 HTR6 3031/4885HRH4 1240/4885HTT 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.